Donepezil, rivastigmine, galantamine and memantine for ...

More documents

Recommendations

Info

vi Contents Appendix 10 Data extraction: head-tohead comparisons ...................................... 285 Appendix 11 Data extraction: memantine RCTs ........................................................... 297 Appendix 12 Critique of submissions from industry: clinical effectiveness .................... 309 Appendix 13 Critical appraisal of published cost-effectiveness studies (by product) ................................................ 313 Appendix 14 Summary results from cost-effectiveness literature ........................ 337 Appendix 15 Critical appraisal of costeffectiveness models submitted to NICE by manufacturers/sponsors ......................... 345 Appendix 16 Figures showing the progression of AD over time using the AHEAD predictive risk equation for FTC, where no mortality effect is present in the SHTAC model ............................................ 357 Appendix 17 Resource use data from OPCS survey of elderly with cognitive disability .... 359 Appendix 18 Sensitivity analysis, against deterministic results, selected one-way and multiple sensitivity analysis using the model with parameter/input variations ................. 361 Health Technology Assessment reports published to date ....................................... 363 Health Technology Assessment Programme ................................................ 375
AChEI acetylcholinesterase inhibitor AD Alzheimer’s disease ADAS-cog Alzheimer’s Disease Assessment Scale, cognitive subscale ADCS/ADL AD Cooperative Study Activities of Daily Living inventory ADFACS Alzheimer’s Disease Functional Assessment and Change Scale ADL Activities of Daily Living AE adverse event AHEAD Assessment of Health Economics in Alzheimer’s Disease APP amyloid precursor protein BADLS Bristol Activities of Daily Living Scale BGP Behavioural Rating Scale for Geriatric Patients BNF British National Formulary BOI burden of illness BVRT Benton Visual Retention Test CCOHTA Canadian Coordinating Office for Health Technology Assessment CCT controlled clinical trial CDR Clinical Dementia Rating Scale CDR-SB Clinical Dementia Rating Scale – Sum of the Boxes CEA cost-effectiveness analysis CEAC cost-effectiveness acceptability curve CERAD Consortium to Establish a Registry for Alzheimer’s Disease CGIC Clinical Global Impression of Change CGRS Crichton Geriatric Rating Scale CI confidence interval CIBIC Clinician’s Interview-based Impression of Change List of abbreviations © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 1 CMB Computerised Memory Battery CMCS Caregiver-rated Modified Crichton Scale CPS Cognitive Performance Scale CSHA Canadian Study of Health and Aging CSRI Client Service Receipt Inventory CT computed tomography CUA cost–utility analysis DAD Disability Assessment for Dementia DLB dementia with Lewy bodies DSM Diagnostic and Statistical Manual of Mental Disorders DSS Department of Social Services DSST Digit Symbol Substitution Test EOAD early-onset Alzheimer’s disease EPS extrapyramidal symptoms FAST Functioning Assessment Staging Scale FLD frontal lobe dementia FOME Fuld Object Memory Evaluation FTC full-time care GBS Gottfries–Bråne–Steen GDS Global Deterioration Scale GHQ-30 General Health Questionnaire 30 HUI Health Utilities Index (version 2 and 3) IADL Instrumental Activities of Daily Living ICD-10 International Classification of Diseases ICER incremental cost-effectiveness ratio IDDD Interview for Deterioration in Daily Living Activities in Dementia continued vii
Page 1 and 2: Health Technology Assessment 2006;
Page 3 and 4: The clinical and cost-effectiveness
Page 5 and 6: Objectives: To provide an update re
Page 7: List of abbreviations .............
Page 11 and 12: Epidemiology and background Alzheim
Page 13: Galantamine Five published economic
Page 17 and 18: Description of underlying health pr
Page 19 and 20: TABLE 1 Estimated prevalence of AD
Page 21 and 22: as one component of their care. A n
Page 23 and 24: The a priori methods used for syste
Page 25: Data synthesis Data were synthesise
Page 28 and 29: 14 Clinical effectiveness TABLE 3 C
Page 30 and 31: 16 Clinical effectiveness TABLE 3 C
Page 32 and 33: 18 Clinical effectiveness particula
Page 34 and 35: 20 Clinical effectiveness Compariso
Page 36 and 37: 22 Clinical effectiveness TABLE 6 M
Page 38 and 39: 24 Clinical effectiveness donepezil
Page 46 and 47: 32 Clinical effectiveness DAD The D
Page 48 and 49: 34 Clinical effectiveness clinical
Page 50 and 51: 36 Clinical effectiveness TABLE 10
Page 54 and 55: 40 Clinical effectiveness statistic
Page 58 and 59:
44 Clinical effectiveness Compariso
Page 60 and 61:
46 Clinical effectiveness Summary:
Page 62 and 63:
48 Clinical effectiveness differenc
Page 64 and 65:
50 Clinical effectiveness TABLE 22
Page 66 and 67:
52 Clinical effectiveness This appe
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
58 Clinical effectiveness Compariso
Page 74 and 75:
Page 76 and 77:
62 Clinical effectiveness placebo [
Page 78 and 79:
Page 80 and 81:
66 Clinical effectiveness (24 mg/da
Page 82 and 83:
Page 84 and 85:
70 Clinical effectiveness ● One R
Page 86 and 87:
72 Clinical effectiveness by the pa
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
78 Clinical effectiveness donepezil
Page 94 and 95:
80 Evidence from systematic reviews
Page 96 and 97:
82 Economic analysis TABLE 48 Chara
Page 98 and 99:
84 TABLE 49 Economic analysis Outli
Page 100 and 101:
86 Economic analysis The UK study r
Page 102 and 103:
88 Economic analysis The AD2000 stu
Page 104 and 105:
90 Economic analysis term). Where w
Page 106 and 107:
92 Economic analysis published econ
Page 108 and 109:
94 Economic analysis Fenn and Gray
Page 110 and 111:
96 Economic analysis one another. W
Page 112 and 113:
98 Economic analysis outcomes: (1)
Page 114 and 115:
100 Economic analysis respond to ga
Page 116 and 117:
102 Economic analysis donepezil, ri
Page 118 and 119:
104 Economic analysis of this study
Page 120 and 121:
106 Economic analysis independent,
Page 122 and 123:
108 Economic analysis classificatio
Page 124 and 125:
110 Economic analysis survey studie
Page 126 and 127:
112 Economic analysis vascular deme
Page 128 and 129:
114 Economic analysis Livingston an
Page 130 and 131:
116 Economic analysis sensitive to
Page 132 and 133:
118 Economic analysis Neumann and c
Page 134 and 135:
120 Economic analysis The model str
Page 136 and 137:
122 Economic analysis CEA, given th
Page 138 and 139:
124 Economic analysis TABLE 70 Key
Page 140 and 141:
126 Economic analysis TABLE 73 Prof
Page 142 and 143:
128 Economic analysis Probability o
Page 144 and 145:
130 Economic analysis Results are s
Page 146 and 147:
132 Economic analysis 4. The model
Page 148 and 149:
134 Economic analysis perspective e
Page 150 and 151:
136 Economic analysis indicating th
Page 153:
Ongoing research, with relevance to
Page 157:
The increasing numbers of the very
Page 160 and 161:
146 Discussion and conclusions dose
Page 162 and 163:
148 Discussion and conclusions effo
Page 164 and 165:
150 Discussion and conclusions Stre
Page 167 and 168:
1. Clegg A, Bryant J, Nicholson T,
Page 169 and 170:
placebo-controlled study of donepez
Page 171 and 172:
94. Brooks E, Deal L. The effect of
Page 173 and 174:
of memantine in patients with moder
Page 175:
This version of HTA monograph volum
Page 179 and 180:
376 Health Technology Assessment Pr
Page 181:
378 Health Technology Assessment Pr
show all

Donepezil, rivastigmine, galantamine and memantine for ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?